Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$26.25 USD

26.25
448,972

+0.15 (0.57%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $26.24 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Pacira BioSciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 279 289 656 522 292
Receivables 106 98 96 53 48
Notes Receivable 0 0 0 0 0
Inventories 104 96 99 65 58
Other Current Assets 22 15 15 12 11
Total Current Assets 510 498 866 652 409
Net Property & Equipment 174 184 188 137 105
Investments & Advances 2 37 0 109 76
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 144 160 153 106 0
Intangibles 647 704 769 196 204
Deposits & Other Assets 36 27 22 0 0
Total Assets 1,574 1,681 2,075 1,275 831
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 350 150 0
Accounts Payable 16 15 11 10 13
Current Portion Long-Term Debt 9 34 24 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 64 90 128 71 70
Income Taxes Payable 0 0 0 0 1
Other Current Liabilities 0 0 0 15 18
Total Current Liabilities 97 148 521 253 108
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 10 0 0
Convertible Debt 399 405 339 313 306
Long-Term Debt 115 251 335 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 38 38 67 17 21
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 704 906 1,345 655 476
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 977 924 942 873 754
Retained Earnings -107 -149 -212 -254 -399
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 870 775 730 620 355
Total Liabilities & Shareholder's Equity 1,574 1,681 2,075 1,275 831
Total Common Equity 870 775 730 620 355
Shares Outstanding 46.40 45.80 44.50 43.40 41.70
Book Value Per Share 18.75 16.92 16.41 14.28 8.51

Fiscal Year End for Pacira BioSciences, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 279 235 221 174
Receivables NA 106 97 99 93
Notes Receivable NA 0 0 0 0
Inventories NA 104 97 92 93
Other Current Assets NA 22 19 17 16
Total Current Assets NA 510 447 429 376
Net Property & Equipment NA 174 176 180 182
Investments & Advances NA 2 0 0 8
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 144 152 156 168
Intangibles NA 647 661 675 689
Deposits & Other Assets NA 36 36 36 32
Total Assets NA 1,574 1,534 1,542 1,523
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 16 17 24 17
Current Portion Long-Term Debt NA 9 9 20 11
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 64 60 56 62
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 97 94 109 99
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 399 398 397 405
Long-Term Debt NA 115 118 135 138
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 36 33 51
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 704 703 734 755
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 977 963 951 936
Retained Earnings NA -107 -132 -143 -168
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 870 832 808 768
Total Liabilities & Shareholder's Equity NA 1,574 1,534 1,542 1,523
Total Common Equity 0 870 832 808 768
Shares Outstanding 46.50 46.40 46.40 45.90 45.90
Book Value Per Share 0.00 18.75 17.92 17.60 16.73